Nantahala Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Nantahala Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-254,803	Closed	-$10.1M	–	160
2026 Q1	$10.1M	Hold	254,803	–	–	0.37%	69
2025 Q4	$6.37M	Sell	254,803 -150,000	-37%	-$3.8M	0.21%	94
2025 Q3	$9.82M	Sell	404,803 -150,000	-27%	-$2.67M	0.34%	68
2025 Q2	$7.29M	Hold	554,803	–	–	0.29%	68
2025 Q1	$7.98M	Buy	554,803 +42,156	+8%	+$690K	0.32%	51
2024 Q4	$8.59M	Hold	512,647	–	–	0.37%	52
2024 Q3	$8.2M	Buy	512,647 +62,647	+14%	+$767K	0.41%	50
2024 Q2	$4.06M	Buy	+450,000	New	+$4.27M	0.24%	71

Nantahala Capital Management's CNTA Position: Q2 2026 in Review

Nantahala Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 254,803 shares — an estimated $10.1M sold.

Nantahala Capital Management first reported a position in CNTA in Q2 2024 and held it in 8 quarters. The position peaked at $10.1M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Nantahala Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Nantahala Capital Management sold 254,803 Centessa Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
Nantahala Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2024 and held it in 8 quarters.
Nantahala Capital Management's Centessa Pharmaceuticals position peaked at $10.1M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.